title: Clinical pharmacology in neuroscience drug discovery: quo vadis?
abstract: Clinical Pharmacology in Neuroscience Drug Discovery in recent years has concentrated on First Time in Human safety and pharmacokinetics. The more traditional pharmacological research in humans has been reduced mainly as a response to the difficulty of developing human pharmacology models in neuroscience diseases. As a consequence, opportunities are being missed to aid in target selection and in target validation. The decision of big Pharma to reduce investment from the Neurosciences has had implications for clinical pharmacologists in this area. It remains to be seen whether academia, government laboratories and contract houses will respond to the challenge of carrying out increased Clinical Pharmacology in the Neurosciences.
authors.affiliation: Via N. Sauro 24, 37047 San Bonifacio, Italy.
authors.forename: David G
authors.initials: DG
authors.lastname: Trist
authors.affiliation: Centre for Human Drug Research, Zernikedreef 10, 2333CL Leiden, The Netherlands. Electronic address: ac@chdr.nl.
authors.forename: Adam
authors.initials: A
authors.lastname: Cohen
authors.affiliation: Alan Bye and Company Limited, Horsham, West Sussex, UK.
authors.forename: Alan
authors.initials: A
authors.lastname: Bye
mesh_terms: D000818:Animals; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods; D004345:Drug Industry / Q000379:methods; D006801:Humans; D008954:Models, Biological; D009488:Neurosciences / Q000379:methods; D010601:Pharmacology, Clinical; D012107:Research Design